Pigment International

REVIEW ARTICLE
Year
: 2016  |  Volume : 3  |  Issue : 2  |  Page : 66--71

Tranexamic acid: An emerging depigmenting agent


Anju George 
 Department of Dermatology, Bangalore Baptist Hospital, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Anju George
“Anjanam,” Chitatumukku P. O., Trivandrum - 695 301, Kerala
India

Tranexamic acid (TXA), an antifibrinolytic drug, is now gaining popularity as a depigmenting agent. It is a synthetic lysine amino acid derivative which mainly blocks the conversion of plasminogen to plasmin by inhibiting plasminogen activator. This results in less free arachidonic acid production, and hence a reduction in the prostaglandin (PG) levels as well. Thus, by reducing PG production, TXA reduces the melanocyte tyrosinase activity and plays an important role in the treatment of melasma, ultraviolet-induced hyperpigmentation, and other postinflammatory hyperpigmentation. It has been tried topically, orally, and intradermally in the management of melasma with minimal adverse effects. However, more randomized trials are needed to fully elucidate the exact mechanism of action, ideal route, frequency, and duration of administration of the drug, along with its potential to treat other pigmentary disorders.


How to cite this article:
George A. Tranexamic acid: An emerging depigmenting agent.Pigment Int 2016;3:66-71


How to cite this URL:
George A. Tranexamic acid: An emerging depigmenting agent. Pigment Int [serial online] 2016 [cited 2020 Feb 27 ];3:66-71
Available from: http://www.pigmentinternational.com/article.asp?issn=2349-5847;year=2016;volume=3;issue=2;spage=66;epage=71;aulast=George;type=0